Paul Eder
About Paul Eder
Paul Eder is a Senior Scientific Officer at The National Institutes of Health, with a strong background in biochemistry and extensive experience in regulated in vitro diagnostic product development. He has held significant roles in assay development and clinical trial protocol execution, and has previously worked as Director of Assay Development at QIAGEN Sciences, Inc.
Work at National Institutes of Health
Paul Eder has been serving as a Senior Scientific Officer at the National Institutes of Health (NIH) since 2020. In this role, he contributes to various scientific projects and initiatives within the organization, leveraging his extensive background in biochemistry and assay development. The NIH is a leading biomedical research institution in the United States, and Eder's work supports its mission to enhance health, lengthen life, and reduce illness and disability.
Education and Expertise
Paul Eder has a strong educational background in biochemistry and biology. He earned a Bachelor of Science degree in Biochemistry from the University of Illinois at Urbana-Champaign, followed by a Ph.D. in Biochemistry from the University of Iowa. He further advanced his studies as a Postdoctoral Fellow at Yale University. Eder also studied at the University of Pennsylvania School of Medicine and the Howard Hughes Medical Institute (HHMI), where he achieved the status of Senior Postdoctoral Scientist. His education underpins his expertise in regulated in vitro diagnostic (IVD) product development.
Previous Experience at QIAGEN Sciences, Inc.
Before joining the NIH, Paul Eder worked at QIAGEN Sciences, Inc. from 2007 to 2011 as the Director of Assay Development. During his four years in this role, he was based in Gaithersburg, MD, where he led efforts in assay development and contributed to the advancement of diagnostic technologies. His experience at QIAGEN provided him with valuable insights into the biotechnology sector and regulatory processes.
Background in Biotechnology R&D
Paul Eder has extensive experience in biotechnology research and development (R&D). His work encompasses feasibility research, assay development, and regulatory submission processes for in vitro diagnostic (IVD) products. He has also been involved in developing pre-clinical and clinical trial protocols, ensuring that they are executed effectively. Additionally, Eder has participated in pilot production and manufacturing transfer processes, which are critical for the successful commercialization of biotechnology products.